Prompong Chaikul - PIRS Old Chief Officer
Insider
Prompong Chaikul is Chief Officer of PIRS Old
| Age | 37 |
| Phone | 857 246 8998 |
| Web | https://www.pieris.com |
PIRS Old Management Efficiency
The company has return on total asset (ROA) of (0.1318) % which means that it has lost $0.1318 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8046) %, meaning that it created substantial loss on money invested by shareholders. PIRS Old's management efficiency ratios could be used to measure how well PIRS Old manages its routine affairs as well as how well it operates its assets and liabilities.PIRS Old currently holds 11.92 M in liabilities with Debt to Equity (D/E) ratio of 0.3, which may suggest the company is not taking enough advantage from borrowing. PIRS Old has a current ratio of 2.51, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about PIRS Old's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Dr III | Cue Biopharma | 49 | |
| Sbastien Desprez | Adaptimmune Therapeutics Plc | N/A | |
| Denise Mueller | Affimed NV | 55 | |
| Christine Granfield | Leap Therapeutics | 57 | |
| Amanda Hamilton | ADC Therapeutics SA | N/A | |
| Joanna Brewer | Adaptimmune Therapeutics Plc | 49 | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Lisa Skelton | ADC Therapeutics SA | 53 | |
| Mary DiBiase | X4 Pharmaceuticals | 64 | |
| Craig Winter | Agenus Inc | N/A | |
| Nathalie Riebel | PDS Biotechnology Corp | N/A | |
| Fiona Bor | Mereo BioPharma Group | N/A | |
| Keith MD | X4 Pharmaceuticals | 54 | |
| III CFA | Checkpoint Therapeutics | 46 | |
| Kenneth MD | Cue Biopharma | 64 | |
| Bertrand Esq | Adaptimmune Therapeutics Plc | 57 | |
| Thomas Rinderknecht | ADC Therapeutics SA | 67 | |
| Susan Romanus | ADC Therapeutics SA | 59 | |
| John Castle | Agenus Inc | N/A | |
| Michael Mulkerrin | ADC Therapeutics SA | 69 | |
| John Lewicki | Mereo BioPharma Group | 73 | |
Management Performance
| Return On Equity | -0.8 | |||
| Return On Asset | -0.13 |
PIRS Old Leadership Team
Elected by the shareholders, the PIRS Old's board of directors comprises two types of representatives: PIRS Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PIRS. The board's role is to monitor PIRS Old's management team and ensure that shareholders' interests are well served. PIRS Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PIRS Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maria Kelman, Executive Relations | ||
| Thomas Bures, Senior CFO | ||
| Prompong Chaikul, Chief Officer | ||
| Ahmed JD, Chief VP | ||
| Gordon MD, Head Oncology | ||
| Stephen JD, President CEO | ||
| Florian Witte, VP Leadership | ||
| Christine Rothe, VP Science | ||
| Hitto Kaufmann, VP Officer | ||
| Frank Vollmering, Vice Resources | ||
| Shane Olwill, Senior Officer |
PIRS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PIRS Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.8 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (1.14) % | |||
| Operating Margin | (0.57) % | |||
| Current Valuation | (8.41 M) | |||
| Shares Outstanding | 1.32 M | |||
| Shares Owned By Insiders | 0.06 % | |||
| Shares Owned By Institutions | 52.92 % | |||
| Number Of Shares Shorted | 23.56 K | |||
| Price To Earning | (6.95) X |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in PIRS Stock
If you are still planning to invest in PIRS Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PIRS Old's history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |